Stockwinners Market Radar for October 20, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:34 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Boeing (BA) said that it regrets and understands concerns raised by the release of a former Boeing test pilot's internal instant messages noting erratic software behavior two years before deadly crashes of its 737 MAX jet, Reuters' Eric Johnson and Bhargav Acharya reported. The planemaker also said it was investigating the "circumstances of this exchange" and regretted the difficulties that the release of messages presented for the U.S. Federal Aviation Administration, the authors noted. 2. Facebook (FB), facing growing skepticism about its digital currency project Libra, said the initiative could use cryptocurrencies based on national currencies such as the dollar, instead of the synthetic one it initially proposed, Reuters's Andrea Shalal reported. David Marcus, who heads the Libra project for Facebook, told a banking seminar the group's main goal remained to create a more efficient payments system, but it was open to looking at alternative approaches for the currency token it would use, the author noted. 3. If cord-cutting accelerates among traditional cable customers, companies like Disney (DIS), WarnerMedia (T) and NBC (CMCSA) will need to win streamers quickly, and if TV viewers stick with their cable bundles for longer than expected, companies could end up having overspent to go over the top, Jack Hough wrote in this week's edition of Barron's. Regardless, there is good money to be made in media stocks in coming years, not just despite the turmoil, but because of it, the author notes. Comcast stacks up better than investors might expect, in part because, for it, cord-cutting is a misnomer, Hough contended, adding that in its markets, Comcast's broadband service is the top means of delivering Netflix (NFLX) and Amazon (AMZN) to homes. 4. "Maleficent: Mistress of Evil" earned $36M from 3,790 theaters in its debut weekend, well behind expectations and over 45% less than the launch of "Maleficent" five years ago. Overseas, the sequel bowed to $117M from 56 markets for an early worldwide total of $153M. Audiences gave the movie an A, while Rotten Tomatoes rating stands at 41%. 5. ConocoPhillips (COP) and GVC Holdings (GMVHF) saw positive mentions in this week's edition of Barron's.

15:38 EDT MasterCard expands Bill Pay Exchange partners - Mastercard (MA) has announced that it is working with several new partners, including ConEd (ED), to roll out Mastercard Bill Pay Exchange. Avidia Bank, Aliaswire, OSG Billing Services and Transactis will be among the first to offer Bill Pay Exchange to their customers. With Bill Pay Exchange, consumers can pay their bills either with cards, real-time payments or from their bank account, and receive confirmation of payment all within their banking app or website. Mastercard will also be testing the solution with eight other partners, including Best Digital Solutions, Inlet, Nordis Technologies, Papaya, Payrailz, Plastiq, RR Donnelley, and Synapse to make the solution available for consumers.

15:25 EDT Alexion ULTOMIRIS receives FDA approval for Atypical Hemolytic Uremic Syndrome - Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration approved ULTOMIRIS for the treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients. This is the first pediatric approval for ULTOMIRIS. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots. The FDA approval is based on data from two global, single-arm open-label studies of ULTOMIRIS - one in adults and one in children, referred to as pediatrics in the study - with aHUS. The pediatric study is ongoing and a total of 14 out of 16 children were enrolled and included in the interim analysis. Efficacy evaluation of Complete TMA Response was defined by hematologic normalization parameters and improved kidney function. In the initial 26-week treatment periods, 54% of adults and 71% of children demonstrated Complete TMA Response. Treatment with ULTOMIRIS resulted in reduced thrombocytopenia in 84% of adults and 93% of children, reduced hemolysis in 77% of adults and 86% of children, and improved kidney function in 59% of adults and 79% of children. The most frequently observed adverse reactions reported in these studies were upper respiratory tract infection, diarrhea, nausea, vomiting, headache, hypertension and pyrexia. Serious meningococcal infections have occurred in patients treated with ULTOMIRIS. To minimize the risk for patients, specific risk-mitigation plans, including a REMS, have been established for ULTOMIRIS. Regulatory filings for marketing authorizations of ULTOMIRIS for the treatment of aHUS in the European Union and Japan are under review with regulators.